Estrogen receptor gene amplification occurs rarely in ovarian cancer

Modern Pathology

Volumn 22, Issue 2, 2009, Pages 191-196

  Issa, Rana M ^a   Lebeau, Annette ^a   Grob, Tobias ^a   Holst, Frederik ^a   Moch, Holger ^b   Terracciano, Luigi ^c   Choschzick, Matthias ^a   Sauter, Guido ^a   Simon, Ronald ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Estrogen receptor gene; Estrogen receptors; Fluorescence in situ hybridization; Immunohistochemistry; Ovarian cancers

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA;

ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE NUMBER; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 59149085060     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.130     Document Type: Article

References (41)

1. Kurman RJ, (ed). Blaustein's Pathology of the Female Genital Tract. 5th edn. Springer: New York, 2002, 791p.
2. Smyth JF, Gourley C, Walker G, et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 2007;13:3617-3622.
3. Vang R, Whitaker BP, Farhood AI, et al. Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. Int J Gynecol Pathol 2001;20:252-259.
4. Teufel G, Geyer H, de Gregorio G, et al. Estrogen and progesterone receptors in malignant ovarian neoplasms. Geburtshilfe Frauenheilkd 1983;43:732-740.
5. De Sousa Damião R, Fujiyama Oshima CT, Stávale JN, et al. Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries. Oncol Rep 2007;18:25-32.
6. Kommoss F, Pfisterer J, Thome M, et al. Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecol Oncol 1992;47:317-322.
7. Rosen DG, Huang X, Deavers MT, et al. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 2004;17:790-797.
8. Vang R, Gown AM, Barry TS, et al. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol 2006;19:97-105.
9. Van Doorn HC, Burger CW, van der Valk P, et al. Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses. J Clin Pathol 2000;53:201-205.
10. Lindgren PR, Cajander S, Bäckström T, et al. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol 2004;221:97-104.
11. Lindgren P, Backstrom T, Mahlck CG, et al. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. Int J Oncol 2001;19:31-38.
12. Van Mieghem T, Abeler VM, Moerman P, et al. CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma. Gynecol Oncol 2005;99:493-496.
13. Cardillo MR, Petrangeli E, Aliotta N, et al. Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 1998;17:231-237.
14. Farinola MA, Gown AM, Judson K, et al. Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors. Int J Gynecol Pathol 2007;26:375-382.
15. Ho SM. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 2003;1:73.
16. Høgdall EV, Christensen L, Høgdall CK, et al. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep 2007;18:1051-1059.
17. Perez-Gracia JL, Carrasco EM. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol 2002;84:201-209.
18. Langdon SP, Crew AJ, Ritchie AA, et al. Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. Eur J Cancer 1994;30A:682-686.
19. Makar AP. Hormone therapy in epithelial ovarian cancer. Endocr Relat Cancer 2000;7:85-93.
20. Clinton GM, Hua W. Estrogen action in human ovarian cancer. Crit Rev Oncol Hematol 1997;25:1-9.
21. Cunat S, Hoffmann P, Pujol P. Estrogens and epithelial ovarian cancer. Gynecol Oncol 2004;94:25-32.
22. Holst F, Stahl PR, Ruiz C, et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007;39:655-660.
23. Wagner U, Bubendorf L, Gasser TC, et al. Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am J Pathol 1997;151:753-759.
24. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481.
25. Wu R, Lin L, Beer DG, et al. Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas. Am J Pathol 2003;162:1603-1610.
26. Leary JA, Edwards BG, Houghton CR, et al. Amplification of HER-2/neu oncogene in human ovarian cancer. Int J Gynecol Cancer 1992;2:291-294.
27. Lassus H, Sihto H, Leminen A, et al. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med 2006;84:671-681.
28. Dimova I, Raitcheva S, Dimitrov R, et al. Correlations between c-myc gene copy-number and clinicopathological parameters of ovarian tumours. Eur J Cancer 2006;42:674-679.
29. Masciullo V, Scambia G, Marone M, et al. Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas. Int J Cancer 1997;74:390-395.
30. Courjal F, Louason G, Speiser P, et al. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 1996;69:247-253.
31. Diebold J, Mösinger K, Peiro G, et al. 20q13 and cyclin D1 in ovarian carcinomas. Analysis by fluorescence in situ hybridization. J Pathol 2000;190:564-571.
32. Xin XY. The amplification of c-myc, N-ras, c-erb B oncogenes in ovarian malignancies. Zhonghua Fu Chan Ke Za Zhi 1993;28:405-407, 42.
33. Bian M, Fan Q, Huang S. Amplification of proto-oncogenes C-myc, C-N-ras, C-Ki-ras, C-erbB2 in ovarian carcinoma. Zhonghua Fu Chan Ke Za Zhi 1995;30:406-409.
34. Li YF, Hu W, Fu SQ, et al. Aromatase inhibitors in ovarian cancer: is there a role?. Int J Gynecol Cancer 2007; doi:10.1111/j.1525-1438.2007. 01075.x, e-pub ahead of print.
35. Papadimitriou CA, Markaki S, Siapkaras J, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 2004;66:112-117.
36. Balbi G, Piano LD, Cardone A, et al. Second-line therapy of advanced ovarian cancer with GnRH analogs. Int J Gynecol Cancer 2004;14:799-803.
37. Trope C, Marth C, Kaern J. Tamoxifen in the treatment of recurrent ovarian carcinoma. Eur J Cancer 2000;36(Suppl 4):S59-S61.
38. Levine D, Park K, Juretzka M, et al. Phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer 2007;110:2448-2456.
39. Hasan J, Ton N, Mullamitha S, et al. Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer 2005;93:647-651.
40. Wagner U, du Bois A, Pfisterer J, et al. AGO Ovarian Cancer Study Group: Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy - a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol 2007;105:132-137.
41. Karagol H, Saip P, Uygun K, et al. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. Med Oncol 2007;24:39-43.